山茱萸总萜对KKay糖尿病小鼠的治疗作用研究

Effects of terpenes from Cornus Fructus on KKay diabetic mice

目的观察山茱萸总萜对KKay糖尿病小鼠的治疗作用。方法选择KKay糖尿病小鼠模型,分别以低、中、高剂量(0.05、0.10、0.20 g/kg)的山茱萸总萜ig给药5周。每天给药前观察动物一般状况;给药前及给药期间每周测定1次小鼠体质量、空腹血糖;给药第5周,进行ip葡萄糖耐量试验(IPGTT),采血测定胰岛素(Ins)、糖化血红蛋白(Hb A1c)、糖化血清蛋白(GSP)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)水平,计算胰岛素抵抗指数(IR)。结果与模型组比较,山茱萸总萜可以剂量相关性地减轻KKay小鼠体质量,高剂量组第1、2和5周差异显著(P<0.05);各剂量组自给药第1周起即可显著降低空腹血糖水平(P<0.05、0.01);高剂量组显著降低IPGTT中小鼠血糖-时间曲线下面积(P<0.05);山茱萸总萜可以剂量相关性地降低Ins、Hb A1c、GSP、TC、TG、LDL水平、降低IR。结论山茱萸总萜对于KKay小鼠糖尿病相关症状和指标具有剂量相关性的改善作用,可改善脂质代谢紊乱,提示其在治疗伴有胰岛素抵抗和脂质代谢紊乱的轻、中度2型糖尿病方面具有良好的应用前景。

Objective To investigate effects ofterpenes from Comus Fructus （TCF） on KKay diabetic mice. Methods KKay diabetic mice were ig administered with different doses （0.05, 0.10, and 0.20 g/kg） of TCF for 5 weeks. Animal general condition was observed before dosing every day. Body weight and fasting blood glucose were measured once per week before and during administration. In the fifth week, ip glucose tolerance test （IPGTT） was employed, and levels of insulin （Ins）, glycosylated hemoglobin （HbAlc）, glycosylated serum protein （GSP）, total cholesterol （TC）, triglyceride （TG）, high density lipoprotein （HDL）, and low density lipoprotein （LDL） in blood were determined. The insulin resistance index （IR） was calculated. Results Compared with model group, TCF dose-dependently reduced body weight and the high dose group was significantly different in first, second and fifth weeks （P 〈 0.05）. The fasting blood glucose level （P 〈 0.05, 0.01） was significantly lower since the first week of each dose group. High dose of TCF significantly reduced the area under the curve of blood glucose versus time profile （P 〈 0.05）. TCF can dose dependently decreased the levels of Ins, HbAlc, GSP, TC, TG, LDL, and IR. Conclusion TCF can obviously improve the hyperglycemia and insulin resistance in KKay mice. In addition, TCF could improve the disorder oflipids metabolism. Based on these results, we conclude that TCF is a potential candidate for clinical treatment in mild-moderate type 2 diabetes mellitus with insulin resistance and lipid metabolism disorder.